OA
LMAT icon

Operose Advisors’s LeMaitre Vascular LMAT Stock Holding History

Operose Advisors’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-299
Closed -$16.3K – 679
2023
Q3 		$16.3K Buy
+299
New +$17.7K 0.01% 503

Other funds holding LMAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Operose Advisors's LMAT Position: Q4 2023 in Review

Operose Advisors sold out of LeMaitre Vascular (LMAT) in Q4 2023, closing a stake of 299 shares — an estimated $16.3K sold.

Operose Advisors first reported a position in LMAT in Q3 2023 and held it in 1 quarter. The position peaked at $16.3K in Q3 2023. 227 funds tracked by Wall St. Rank hold LMAT as of Q4 2023.

  • Operose Advisors reported no remaining LeMaitre Vascular position as of Q4 2023 after selling out during the quarter.
  • Operose Advisors sold 299 LeMaitre Vascular shares in Q4 2023, an estimated $16.3K.
  • Operose Advisors first reported a position in LeMaitre Vascular in Q3 2023 and held it in 1 quarter.
  • Operose Advisors's LeMaitre Vascular position peaked at $16.3K in Q3 2023.
  • 227 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q4 2023.

Based on Operose Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.